Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Inclusion Criteria: * Histology diagnoses epithelial ovarian, primary peritoneal, or fallopian tube(Stage II, III or IV)either optimal or suboptimal after initial surgery. * All patients must have had appropriate surgery for ovarian, peritoneal, or fallopian tube carcinoma with tissue available for histologic evaluation * Histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant brenner tumor, adenocarcinoma NOS. * GOG(Gynecologic Oncology Group)performance status of 0,1,2 * Entered within 12 weeks of most recent surgery performed for diagnosis. * Patients must have adequate bone marrow function, renal function,hepatic function, neurologic function, blood coagulation parameters within normal limits * Sign approved consent form. Exclusion Criteria: * Patients who have received prior treatment other than initial surgery * Patients who have received prior radiotherapy to any portion of their abdominal cavity or pelvis * Patients with acute hepatitis or active infection * Patients with active bleeding * Patients with unstable angina * Patients with history of invasive malignancies with the exception of nonmelanoma skin cancer and localized breast cancer. * Patients who have received any target therapy or hormonal therapy for management of their ovarian cancer. * Patients with synchronous primary endometrial cancer. * Patients with epithelial tumors of low malignant potential * Serious non healing wound, ulcer or bone fracture. * Patients with history or evidence of CNS(central nervous system disease) * Patients under 18 years old. * Patients who have received prior therapy with anti-VEGF(vascular endothelial growth factor) drug, bevacizumab * Patients who have a history of allergic reaction to polysorbate 80.